STOCK TITAN

Latigo Biotherapeutics grants CEO 2.21M stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Latigo Biotherapeutics, Inc. (LTGO) reported a grant to President and CEO Todd N. Smith of 2,207,516 employee stock options on November 15, 2026, with a $13.11 exercise price. The options cover 2,207,516 shares of common stock and expire November 14, 2036. The disclosed schedule says 25% vests on November 3, 2027, with 1/48th of the total shares vesting on each monthly anniversary thereafter.

Insider SMITH TODD N
Role President and CEO
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F1 2,207,516 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 2,207,516 options (Direct)
Footnotes (1)
  1. F1. 25% of the total shares subject to this option shall vest on November 3, 2027, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
Options granted 2,207,516 options Granted November 15, 2026
Exercise price $13.11 per share Price to exercise the options
Underlying common shares 2,207,516 shares Shares covered by the options
Initial vesting portion 25% Vests November 3, 2027
Subsequent vesting portion 1/48th of the total shares Vests on each monthly anniversary thereafter
Expiration date November 14, 2036 Options expire on this date
Employee Stock Option financial
"Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"The options have a $13.11 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"25% of the total shares subject to this option shall vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
monthly anniversary financial
"on each monthly anniversary thereof"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did LTGO's CEO receive?

President and CEO Todd N. Smith received 2,207,516 employee stock options on November 15, 2026. The options have a $13.11 exercise price and cover common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SMITH TODD N

(Last)(First)(Middle)
C/O LATIGO BIOTHERAPEUTICS, INC.
1300 RANCHO CONEJO BLVD., SUITE 305

(Street)
THOUSAND OAKS CALIFORNIA 91320

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [ LTGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$13.1111/15/2026A2,207,516 (1)11/14/2036Common Stock2,207,516$02,207,516D
Explanation of Responses:
1. 25% of the total shares subject to this option shall vest on November 3, 2027, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof.
/s/ Sabrina Nieder, Attorney-in-Fact11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading